Compare Agilysys Inc (AGYS) vs Hims and Hers Health Inc (HIMS) Price & Performance

Agilysys (AGYS) trades at $111.00, up 0.17% with strong bullish technical indicators and unanimous analyst support. The stock shows robust fundamentals with 62.61% gross margins and accelerating revenue growth, projected to reach $319 million in 2026. Recent earnings beats and positive guidance highlight the company's momentum in hospitality technology solutions.

The outlook remains positive with 100% buy ratings and a $110 consensus target, though high valuation multiples (P/E 81.05) and overbought RSI levels suggest near-term consolidation risks. Long-term growth drivers include AI integration and subscription revenue expansion, but investors should monitor execution against elevated expectations.

Hims & Hers Health trades at $38.28, up 4.02% today, showing strong momentum near its 52-week high. The stock exhibits a bullish technical trend with support at $37 and resistance at $39. Fundamentally, revenue reached $2.35 billion in 2025 with a gross margin of 71.72%, though net income turned negative in 2026. Recent news highlights growth in weight-loss subscriptions and a price target increase from Canaccord Genuity to $40 (July 1, 2026).

The outlook is mixed: bullish technicals and subscriber growth contrast with high valuation multiples (P/E 57.14) and recent earnings misses. Key risks include execution in competitive telehealth and reliance on obesity drug trends. Analysts are cautious with 65% hold ratings, consensus target $33.43 suggests limited upside from current levels.